Court R. Turner, J.D.

President, CEO and Director

Court R. Turner, J.D. is the president, CEO and director of Synthorx.  He is also a venture partner at Avalon Ventures; Mr. Turner joined Avalon in 2008 as an advisor and became a venture partner in 2010. As a venture partner and serial entrepreneur, Mr. Turner has served as the president, CEO and director of Carolus Therapeutics, COO and director of Afraxis, and director of Zacharon Pharmaceuticals (acquired by Biomarin), and director at Otonomy. Additionally, Mr. Turner led Avalon’s investment and served as founding CEO and chairman for RQx Pharmaceuticals (signed exclusive deal with Genentech). He currently serves as a board observer of Cardeas Pharma. Prior to joining Avalon Ventures, he spent 11 years in leadership positions in San Diego biotech companies, including Kalypsys and Aurora Biosciences. Mr. Turner received a J.D. from the University of San Diego School of Law and B.S. in psychology from San Diego State University.

Patrick J. Doyle

Chief Business Officer

Patrick J. Doyle is the chief business officer of Synthorx. Mr. Doyle has more than 20 years of experience with worldwide business development, licensing and leadership of the pharmaceutical R&D process. Prior to joining Synthorx, Mr. Doyle held various C-suite positions at Kinemed, Kareus Therapeutics, Syntaxin and Metabolex, where he grew the business platforms significantly via global collaborations and financing. In addition, Mr. Doyle has held top management positions at Novo Nordisk, Roche and PPD. He completed his Ph.D. thesis and received his B.S. in pharmacology from the University of Sunderland in England.


Floyd Romesberg, Ph.D.

Scientific Founder and Director

Floyd E. Romesberg, Ph.D. is the scientific founder and a member of the board of directors of Synthorx. Prior to Synthorx, he served as the scientific co-founder and a member of the board of directors of RQx Pharmaceuticals (acquired by Genentech) and Achaogen, two biopharmaceutical companies focused on developing new antibiotics. Dr. Romesberg is also an associate professor of chemistry at The Scripps Research Institute. His academic research laboratory uses a broad range of interdisciplinary techniques, including non-linear optical spectroscopy, organic chemistry, microbiology, and genetics, to study different aspects of evolution. This work has been described in more than 100 peer-reviewed publications and has been funded by the National Institutes of Health, National Science Foundation, and Office of Naval Research. Dr. Romesberg is best known for developing unnatural base pairs for the expansion of the genetic alphabet and is also working to develop novel antibiotics, as well as to understand how evolution tailors protein dynamics and how cellular stress and DNA damage induce cell-cycle checkpoint responses and mutations. Dr. Romesberg performed his postdoctoral training with Dr. Peter Schultz at the University of California, Berkeley.  He received a Ph.D. in physical organic chemistry from Cornell University and a B.S. in chemistry from The Ohio State University.